Europe
Dicerna and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases.
Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M.
Dotmatics announced Version 5.2, a new release of the company’s informatics suite designed to enhance the end user experience and make scientists more productive.
Net product revenue in the third quarter of 2017 achieved record levels.
The scientist was among the nearly one dozen people injured on Oct. 31.
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.
Astra and its MedImmune division announced that two Phase III clinical trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.
Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.
The FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18 to 1 to recommend Indivior’s RBP-6000 to treat opioid use disorder.
PRESS RELEASES